| Name | Serdemetan |
| Description | Serdemetan (JNJ-26854165) is an orally bioavailable HDM2 antagonist with potential antineoplastic activity. |
| Cell Research | Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK(Only for Reference) |
| In vitro | In both solid and ALL transplant tumor models, oral administration of JNJ-26854165 (20 mg/kg) significantly altered EFS distribution. |
| In vivo | In leukemia cell lines, JNJ-26854165 inhibits cell growth and induces apoptosis, demonstrating inhibitory effects on OCI-AML-3 (IC50=0.24 μM), MOLM-13 (IC50=0.33 μM), NALM-6 (IC50=0.32 μM), and REH (IC50=0.44 μM). Additionally, it inhibits cell proliferation in various human cancer cell lines (H460, A549, p53-WT-HCT116, and p53-null-HCT116). |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 2 mg/mL (6.09 mM), Sonication is recommended.
H2O : < 1 mg/mL (insoluble or slightly soluble)
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.09 mM), Sonication is recommended.
DMSO : 50 mg/mL (152.25 mM), Sonication is recommended.
|
| Keywords | Ubiquitin ligase | Ubiquitin conjugating enzyme | Ubiquitin activating enzyme | Serdemetan | p53 | MDM-2/p53 | Mdm2 | JNJ26854165 | JNJ 26854165 | Inhibitor | inhibit | HDM2 | E3Enzyme | E3 ligating enzyme | E3 Enzyme | E2Enzyme | E2 Enzyme | E2 conjugating enzyme | E1Enzyme | E1/E2/E3 Enzyme | E1 Enzyme | E1 activating enzyme | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Metabolism Compound Library | Glutamine Metabolism Compound Library | Anti-Cancer Clinical Compound Library | Pyroptosis Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
